Top Markets
#1 ADO Protocol ADO Protocol +329.37%
#2 GoPlus Security GoPlus Security +53.93%
#3 Verus Coin Verus Coin +43.47%
#4 Nockchain Nockchain +40.54%
#5 The Black Bull The Black Bull +39.50%
#6 Starpower Starpower +35.61%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +34.02%
#8 Tutorial Tutorial +27.75%
#9 Fake World Assets Fake World Assets +24.98%
#10 GAIB AID GAIB AID +24.67%
Coin of the day
ADO Protocol ADO Protocol
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
NuCana plc NuCana plc

NuCana plc

NCNA
Classificação em ações #32729
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Preço da ação
$1.56
Valor de mercado
$9.44M
Variação (1 dia)
-2.20%
Variação (1 ano)
-58.31%
País
GB
Negociar NuCana plc (NCNA)

Categoria

Healthcare
Histórico de desdobramentos de ações de NuCana plc (NCNA)
As ações NuCana plc (símbolo: NCNA) passaram por um total de 0 desdobramentos.
O desdobramento mais recente ocorreu em Aug 17, 2026.
Uma ação NCNA comprada antes de Aug 17, 2026 equivaleria hoje a 0 ações NCNA.
Lista de desdobramentos de ações
Ano Desdobramento Multiplicador Multiplicador cumulativo
Não há dados suficientes para as datas fornecidas.
Desdobramentos de ações de empresas semelhantes ou concorrentes
Empresa Número de desdobramentos de ações Multiplicador cumulativo País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0 -
BE